Beyond Immunotherapies

Targeted therapies continue to churn out new oncology treatments meeting unmet medical needs among cancer patients around the world. Forrest Anthony, MD, PhD and Senior Director, Head of Oncology Center of Excellence, QuintilesIMS takes a look at some of the most promising targeted therapies on the healthcare horizon, including FLT3 inhibitors for Acute Myelogenous Leukemia, Antibody Drug Conjugates and Cyclin-dependent kinases (CDK) 4/6 for estrogen-receptor-positive breast cancer.

To view the full article click here.

For focused content relating to the challenges of immuno-oncology trials please click here.